The role of presepsin as a diagnostic and prognostic utility in early detection of bacterial sepsis in liver cirrhosis patients- a prospective cohort study

Liver cirrhosis (LC) and its complications are among the leading causes of mortality worldwide, reaching 30% per month and 63 % per year. Bacterial infections are the precipitating factors of LC decompensation, acute-on-chronic liver failure development, and hepatic encephalopathy (HE). The early diagnosis and treatment of infections and sepsis in LC are associated with increased patient survival. Postponing the antibiotherapy initiation for as long as one hour increases the mortality rate by 7.6% Background and Emerging Need High clinical need- infections in dcld patients lead to rapid clinical deterioration, organ failure, higher mortality. Traditional biomarkers such as C-reactive protein (CRP) and procalcitonin (PCT) often have limited sensitivity and specificity Presepsin is a novel biomarker showing superior early sensitivity and correlation with disease severity. There is currently a lack of prospective Indian data evaluating presepsin in dcld patients, highlighting the need for better early risk stratification tools. Unmet Need and Potential Impact No sensitive, validated prognostic biomarker currently exists for predicting clinical severity in decompensated liver disease. Early identification of high-risk patients could enable prompt interventions, reduce ICU admissions, and improve survival outcomes